Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Celgene recommits to Epizyme, adding $620M in cancer drug bonuses
Celgene recommits to Epizyme, adding $620M in cancer drug bonuses
Celgene recommits to Epizyme, adding $620M in cancer drug bonuses
Submitted by
admin
on July 9, 2015 - 9:56pm
Source:
Fierce Biotech
News Tags:
Celgene
Epizyme
Headline:
Celgene recommits to Epizyme, adding $620M in cancer drug bonuses
Do Not Allow Advertisers to Use My Personal information
